Skip to content
Curium
-
Curium enters radioligand therapy market with FDA approval of Bexlutry
Developed by Curium, Bexlutry is a lutetium-177 dotatate injection that references Novartis’ Lutathera, which is approved to treat gastroenteropancreatic neuroendocrine tumors (GEP NETs).